VANCOUVER, BC, January 26, 2022 /CNW/ – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSXV: NU) (OTCQB: NRXCF) (FSE: 1N9), an innovative technology company that develops products, licenses intellectual property and technologies for B2B partnerships and the nutraceutical industry, announces that in order to lead capital to other activities, it will delist its common stock from the OTCQB. The delisting will be effective before the opening of the markets on February 1, 2022.

The Company expects that its common stock may subsequently be eligible for listing on the OTC Markets Group’s pink tier if market makers agree to create a market for the Company’s stock. The Company cannot guarantee that trading of its common stock will continue on the OTC Markets Group or otherwise. For quotes or additional information on the OTC Pink market, please visit http://www.otcmarkets.com.

The Company’s shares will continue to trade on the TSXV and the FSE.

About NeutriSci International Inc.

NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Founded in 2009, NeutriSci’s builds sustainable sales models with convenience, chain drug, mass market and supermarket retailers for its products offering co-branding opportunities as well as private label opportunities and services contract manufacturing. For more information, visit: www.neutrisci.com.

On behalf of the Board of Directors of

NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO
Tel: (403) 264-6320

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements contained herein, other than statements of historical fact, should be considered forward-looking. Although the Company believes that the expectations expressed in these forward-looking statements are based on reasonable assumptions, these statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include market prices, the continued availability of capital and financing, and general economic, market or business conditions. There can be no assurance that such statements will prove to be accurate and, therefore, readers are urged to rely on their own assessment of such uncertainties. We undertake no obligation to update forward-looking statements, except as required by applicable law.

The statements in this press release have not been evaluated by the Food and Drug Administration. The products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

SOURCE NeutriSci International Inc.

For further information: For investor inquiries, please contact [email protected]